Therapeutic ultrasound developer EDAP TMS has announced that the St-Augustin Urology Clinic in Bordeaux, France, has successfully treated patients with its Ablatherm high-intensity focused ultrasound (HIFU) technology.
The treatments were successful for the focal treatment of prostate cancer tumors, according to the Lyon, France-based vendor.
Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients whose radiotherapy treatment was not successful, the company stated. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU is undergoing evaluation in a multicenter U.S. phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the Food and Drug Administration, the ENLIGHT U.S. clinical study.
